Logo

Merck’s Keytruda with Gemcitabine and Cisplatin Received the US FDA’s Approval to Treat Biliary Tract Cancer

Share this

Merck’s Keytruda with Gemcitabine and Cisplatin Received the US FDA’s Approval to Treat Biliary Tract Cancer

Shots:

  • The approval was based on the P-III (KEYNOTE-966) clinical trial evaluating Keytruda (200mg) + CT (gemcitabine, 1,000 mg/m2 & cisplatin, 25 mg/m2) vs PBO + CT, randomized in the ratio 1:1, in patients (n=1,069) with locally advanced unresectable/metastatic biliary tract cancer. In both cohorts, patients received Keytruda + CT or PBO + CT on Day 1 followed by CT alone on Day 8 for Q3W
  • The results depicted OS to be 12.7mos. vs 10.9mos with mDOR of 8.3mos. vs. 6.8mos. along with a mPFS of 6.5mos. vs 5.6mos., ORR of 29% vs 29% with CR & PR of 2.1% vs 1.3% & 27% vs 27%
  • The safety results of the study demonstrated a difference of ≥5% incidence in adverse reactions between patients in both cohorts for pyrexia (26% vs 20%), rash (21% vs 13%), pruritus (15% vs 10%) and hypothyroidism (9% vs 2.6%)

Ref: Merck | Image: Merck

Related News:- Merck’s P-III Trial Assessing Keytruda Met its Secondary Endpoint in Renal Cell Carcinoma (RCC) Patients

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions